IDI2-AS1

Across TCGA pan-cancer cohorts, IDI2-AS1 RNA is linked to patient survival in 18 of 34 cancer types, making it the most broadly survival-associated IDI2-AS1 data layer.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher IDI2-AS1 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated IDI2-AS1 expression acts as an unfavorable survival marker, although some lineages such as UVM and HNSC show a favorable association.

ACC, KIRC, and THCA are the cancer types where IDI2-AS1 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	DFS	Median	All	0.216	0.725	<.001	92	view →
KIRC	DFS	Median	All	0.540	0.699	<.001	58	view →
THCA	OS	Quartile	II,III,IV	0.626	1.000	<.001	52	view →
CESC	DFS	Median	All	0.755	0.888	<.001	40	view →
COAD	OS	Median	III,IV	0.589	0.789	.003	37	view →
UVM	DFS	Median	All	0.734	0.491	.012	34	view →
HNSC	OS	Tertile	IV	0.650	0.303	<.001	30	view →
BLCA	DFS	Quartile	All	0.224	0.588	.015	25	view →
KICH	DFS	Quartile	III,IV	0.249	0.816	.007	18	view →
SKCM	DFS	Median	IV	0.187	0.763	.006	16	view →
MESO	DFS	Median	III,IV	0.531	0.304	.005	13	view →
LUAD	DFS	Quartile	IV	0.399	0.880	.006	13	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 18 lineages.

IDI2-AS1–ACC (DFS)

Open the ACC breakdown →